Tag Archives: anti-TNF

June, 2016

• 10 June

  Samsung Bioepis Announces New Late-Stage Data on Three Biosimilars

  

  INCHEON, Korea–(BUSINESS WIRE)–Samsung Bioepis Co., Ltd. today announced new clinical data on its anti-TNF-α portfolio of Benepali® (etanercept), Flixabi® (infliximab) and SB5 (adalimumab) investigational biosimilar candidate. The data will be presented through seven poster presentations and an abstract publication at the Annual European Congress on Rheumatology (EULAR 2016), which is …

  Share

  • Facebook
  • Twitter
  • LinkedIn

April, 2016

• 4 April

  Samsung Bioepis’ Infliximab Biosimilar Recommended for Approval in the European Union

  

  INCHEON, Korea – April 1, 2016 – Samsung Bioepis Co., Ltd. today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on Flixabi® – a biosimilar version of Remicade® (infliximab), also known as SB2 – for the treatment of …

  Share

  • Facebook
  • Twitter
  • LinkedIn